Retrospective data of five advanced melanoma patients with a BRAF mutation in G469R/S/A/T17OdelinsAK did not show any response to BRAFi monotherapy, but two of three patients responded to a combination therapy with BRAFi plus MEKi (60%). This evidence concerns the gene BRAF and melanoma.